Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants
Clinical Pharmacology & Therapeutics · 2023-04 · 113 (4) · 822-831
DOI: 10.1002/cpt.2821 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 31.12.2022. Verfasst von Friederike Holze und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Base…. Hauptthemen laut MEDLINE: Psilocybin. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Psilocybin is being investigated as a potential treatment for psychiatric and neurological disorders. Only a few studies have evaluated the pharmacokinetics (PKs) of psilocybin and have used body weight‐adjusted dosing. Data on PKs and the PK‐pharmacodynamic (PD) relationship of fixed doses that are commonly used are unavailable. The present study characterized the PKs and PK‐PD relationship of 15, 25, and 30 mg of orally administered psilocybin in 28, 23, and 28 healthy subjects, respectively. Plasma levels of unconjugated psilocin (the psychoactive metabolite of psilocybin) and corresponding subjective effects were repeatedly assessed up to 24 hours. PK parameters were determined using compartmental modeling. Concentration‐subjective effect relationships were described using PK‐PD modeling. Mean (95% confidence interval) maximal psilocin concentrations were 11 ng/mL (10‐13), 17 ng/mL (16‐19), and 21 ng/mL (19‐24) after the administration of 15, 25, and 30 mg psilocybin, respectively. Maximal concentrations were reached after an average of 2 hours. Elimination half‐lives were 1.8 hours (1.7–2.0), 1.4 hours (1.2–1.7), and 1.8 hours (1.6–1.9) for 15, 25, and 30 mg psilocybin, respectively. Mean (± SD) durations of subjective effects were 5.6 ± 2.2 hours, 5.5 ± 1.6 hours, and 6.4 ± 2.2 hours, and maximal effects (“any drug” effects) were 58% ± 25%, 73% ± 27%, and 80% ± 18% after 15, 25, and 30 mg psilocybin, respectively. Psilocin exhibited dose‐proportional PKs. The duration and intensity of subjective effects were dose‐dependent. Body weight did not influence pharmacokinetics or the response to psilocybin. These data may serve as a reference for future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
- Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
ORCID-Profile: Friederike Holze, Anna M Becker, Urs Duthaler, Matthias E Liechti
Zitieren
APA
Holze, F., Becker, A. M., Kolaczynska, K. E., Duthaler, U., & Liechti, M. E. (2023). Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. Clinical Pharmacology & Therapeutics, 113(4), 822-831. https://doi.org/10.1002/cpt.2821
Vancouver
Holze F, Becker AM, Kolaczynska KE, Duthaler U, Liechti ME. Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. Clinical Pharmacology & Therapeutics. 2023;113(4):822-831. doi:10.1002/cpt.2821
BibTeX
@article{Holze2023,
author = {Holze, Friederike and Becker, Anna M and Kolaczynska, Karolina E and Duthaler, Urs and Liechti, Matthias E},
title = {Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {113},
number = {4},
pages = {822--831},
doi = {10.1002/cpt.2821}
}
EUVIMED